Search results for Teprotumumab

Teprotumumab Biosimilar – Anti-IGF1R, CD221 mAb – Research Grade, ProteoGenix, PX-TA1242

Description of Teprotumumab Biosimilar - Anti-IGF1R, CD221 mAb - Research Grade Teprotumumab Biosimilar: A Novel Anti-IGF1R Antibody for Therapeutic Targeting of CD221 Teprotumumab Biosimilar, also known as Anti-IGF1R, CD221 mAb – Research Grade, is a promising novel antibody that has shown great potential in the field of targeted therapy. This biosimilar antibody is designed to specifically target the insulin-like growth factor 1 receptor (IGF1R) and has been developed as a biosimilar to Teprotumumab, a FDA-approved monoclonal antibody for the treatment of thyroid eye disease. In this article, we will discuss the structure, activity, and potential applications of this innovative biosimilar antibody. Structure of Teprotumumab Biosimilar Teprotumumab Biosimilar is a recombinant, fully humanized IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two identical heavy chains and two identical light chains, connected by disulfide bonds. The antibody is produced in Chinese hamster ovary (CHO) cells using recombinant DNA technology. The variable region of Teprotumumab Biosimilar is highly specific for the extracellular domain of IGF1R, which is overexpressed in various types of cancer cells. The constant region of the antibody is responsible for mediating effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which are important for its therapeutic activity. Activity of Teprotumumab Biosimilar Teprotumumab Biosimilar has been shown to bind to IGF1R with high affinity and specificity, inhibiting the binding of insulin-like growth factor 1 (IGF1) and insulin-like growth factor 2 (IGF2) to the receptor. This leads to the downregulation of the IGF1R signaling pathway, which is known to play a critical role in cancer cell proliferation, survival, and metastasis. In addition to its direct anti-tumor effects, Teprotumumab Biosimilar has also been shown to enhance the activity of other anti- cancer therapies, such as chemotherapy and radiation therapy. This is due to its ability to sensitize cancer cells to these treatments by inhibiting the IGF1R-mediated survival pathways. Applications of Teprotumumab Biosimilar The primary application of Teprotumumab Biosimilar is in the treatment of various types of cancer, including lung, breast, and prostate cancer. It has also shown promising results in clinical trials for the treatment of thyroid cancer, where IGF1R is known to be overexpressed. Moreover, Teprotumumab Biosimilar has the potential to be used in combination with other anti- cancer therapies, as it has been shown to enhance their activity and overcome resistance to treatment. This could lead to improved outcomes and prolonged survival for cancer patients. Aside from its anti-tumor effects, Teprotumumab Biosimilar has also shown promise in the treatment of other diseases, such as diabetes and metabolic disorders. This is due to the role of IGF1R in regulating glucose metabolism and insulin signaling. Conclusion Teprotumumab Biosimilar is a novel anti-IGF1R antibody with a unique structure and highly specific activity. Its potential applications in cancer treatment and other diseases make it a promising therapeutic option for patients. Further research and clinical trials are needed to fully explore the potential of this biosimilar antibody and its role in improving patient outcomes.

Teprotumumab, Kyinno, KB-1102

Teprotumumab, Abbexa, abx831196

Teprotumumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IGF1R/CD221, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. 8 Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 20163 and was approved by the FDA in January 2020 for the treatment of TED. 7 Thyroid eye disease is a potentially debilitating complication of Graves' Disease involving inflammation and tissue remodeling behind the eye, and previous treatment options typically involved multiple invasive surgeries - teprotumumab is the first drug ever approved for the treatment of TED and therefore represents a significant step forward in the treatment this disease.

Teprotumumab ELISA Kit, ProteoGenix, KPTX161

Description of Teprotumumab ELISA Kit Introduction to Teprotumumab ELISA Kit Teprotumumab is a monoclonal antibody that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of thyroid eye disease (TED). This condition, also known as Graves’ orbitopathy, is an autoimmune disorder that affects the eyes and is associated with an overactive thyroid gland. Teprotumumab is a promising therapeutic target for TED, and its activity can be measured using an ELISA kit. Structure of Teprotumumab Teprotumumab is a fully human monoclonal antibody, meaning that it is derived from human cells and does not contain any animal or bacterial components. It is composed of two identical heavy chains and two identical light chains, which are connected by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa and is made up of 1,331 amino acids. The structure of Teprotumumab is important for its activity as an antibody. It has a specific binding site, called the antigen-binding site, which is located at the tip of each arm of the Y-shaped molecule. This site is responsible for recognizing and binding to its target antigen, which in the case of Teprotumumab is insulin-like growth factor 1 receptor (IGF-1R). Activity of Teprotumumab Teprotumumab works by binding to IGF-1R, which is a protein that is overexpressed in the tissues of patients with TED. IGF-1R is involved in the development of TED, as it promotes inflammation, fibrosis, and tissue expansion in the eye. By binding to IGF-1R, Teprotumumab blocks its activity and prevents these damaging processes from occurring. The activity of Teprotumumab can be measured using an ELISA (enzyme-linked immunosorbent assay) kit. This is a common laboratory technique that uses antibodies to detect and quantify the presence of a specific protein or antigen in a sample. In the case of Teprotumumab, the ELISA kit contains antibodies that are specific for IGF-1R. When a sample containing Teprotumumab is added to the kit, the antibody will bind to the IGF-1R present in the sample, allowing for its detection and measurement. Application of Teprotumumab ELISA Kit The Teprotumumab ELISA kit has several important applications in the development and use of this therapeutic antibody. Firstly, it can be used to measure the levels of Teprotumumab in patient samples, such as blood or tissue samples. This is important for monitoring the effectiveness of treatment and ensuring that patients are receiving the correct dose of the drug. The ELISA kit can also be used to measure the levels of IGF-1R in patient samples. This can provide valuable information about the activity of the disease and the response to treatment. In addition, the ELISA kit can be used in research studies to investigate the role of IGF-1R in TED and to evaluate the efficacy of Teprotumumab in blocking its activity. Overall, the Teprotumumab ELISA kit is an essential tool in the development and use of this promising therapeutic antibody for TED. It allows for the accurate measurement of Teprotumumab levels and provides valuable insights into the activity of the disease and the drug’s effectiveness. With the approval of Teprotumumab by the FDA, this ELISA kit will play a crucial role in improving the lives of patients with TED. Conclusion Teprotumumab is a monoclonal antibody that has shown promising results in the treatment of thyroid eye disease. Its structure, activity, and application can be described in terms of its specific binding

Teprotumumab ELISA Kit, Abbexa, abx395050

Teprotumumab ELISA Kit is a quantitative ELISA kit for detection of Teprotumumab.Teprotumumab is a human IgG1 monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF1R) that is used in the therapy of Graves ophthalmopathy (thyroid eye disease). Graves disease is an autoimmune disease associated with autoantibodies, hyperthyroidism and a distinctive form of eye disease marked by ocular inflammation and proptosis causing eye pain, dryness, redness, and swelling which if severe can cause diplopia (double-vision) and loss of vision. Graves ophthalmopathy is associated with autoantibodies to thyrotropin and hypertrophy of ocular fibroblasts which overexpress the IGF1 receptor. Teprotumumab causes inhibition of IGF1 binding to its receptor and preventing cell activation. IGF1 is a potent modulator of cell growth and inhibitor of programmed cell death, acting via the PI3K-AKT-mTOR pathway. The inhibition of IGF1 signaling decreases fibroblast proliferation and hypertrophy.

Teprotumumab Biosimilar - Research Grade, ichor.bio, ICH5128

Detects human IGF1R

Research Grade Teprotumumab (HY353036), abinScience, HY353036